Pharmaceutical industry drug discovery partnerships

Major pharmaceutical companies are entering large-scale partnerships to advance drug discovery and development through specialized technologies.

In late September 2026, Boehringer Ingelheim expanded its collaboration with Variant Bio to include cardiovascular disease research, building on previous kidney disease work. This deal, utilizing machine learning and statistical genetics, includes potential payments exceeding $250 million. Concurrently, Roche signed a deal with Atavistik Bio worth nearly $2 billion to develop oral treatments targeting difficult-to-reach protein sites.

By early October 2026, the trend of high-value licensing and collaboration continued. Novartis entered an exclusive worldwide licensing agreement with Abogen Biosciences for ABO2203, an experimental mRNA-encoded T-cell engager. The deal includes a $575 million upfront payment, with total potential value reaching approximately $7.8 billion. ABO2203 is designed to treat autoimmune diseases by instructing the body to produce molecules that deplete specific B-cell populations.

Additionally, Sanofi and Regeneron Pharmaceuticals expanded their long-standing antibody alliance to co-develop and co-commercialize four new long-acting immunology antibodies targeting various interleukins. This expansion, which follows their partnership on the eczema drug Dupixent, includes a $1 billion upfront payment to Regeneron.